Video Programs

PODIUM-03 shows retifanlimab plus carboplatin/paclitaxel boosts response and survival, reshaping first-line care for advanced anal cancer.

Cabozantinib offers significant benefits for patients progressing on octreotide LAR, especially those with prior treatments and specific conditions.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, discusses the future of BPCDN treatment and how a collaborative care model should play a role in this rare disease.

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.

The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores the clinical rationale for triplet regimens combining tagraxofusp-erzs (Elzonris), azacitidine (Vidaza), and ventoclax (Venclexta).

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, outlines monitoring parameters and intervention strategies required for patient safety following treatment with tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN).

BPDCN breakthroughs: CD123-targeting tagraxofusp and venetoclax-azacitidine combinations boost remissions, limit myelosuppression, and help reach transplant.

Spot BPDCN fast: skin-first clues, CD123/CD4/CD56 triad, mandatory CNS staging, and transplant-focused remission strategy.

Explore rising HPV-driven anal cancer burden and NCCN first-line choices, with trial data guiding chemo-immunotherapy patient selection.

NCCN updates recommend cabozantinib for neuroendocrine tumors, offering flexibility in treatment options for practitioners and patients.

NCCN updates recommend cabozantinib for neuroendocrine tumors, offering flexibility in treatment options based on patient needs and prior therapies.

Explore advanced treatment options for gastrointestinal neuroendocrine tumors, focusing on real-world case studies and emerging clinical data.

Leyla O. Shune, MD, looks to the future of treatment for patients with chronic graft-versus-host disease (cGVHD).

Explore innovative combination strategies for chronic GVHD treatment, focusing on emerging therapies and their potential to enhance patient outcomes.

Leyla O. Shune, MD, discusses sequencing agents in the in current treatment paradigm for chronic graft-versus-host disease, given the multitude of available FDA-approved agents and additional treatments emerging on the horizon.

Explore the complexities of interpreting clinical trial results versus real-world experiences in chronic GVHD treatment options.

Explore effective third-line treatments for chronic GVHD, focusing on the latest FDA-approved therapies and their impact on patient outcomes.

This segment examines optimal care for patients with early-stage non–small cell lung cancer (NSCLC) relying on coordinated multidisciplinary collaboration.

This case examines effective management of early-stage non–small cell lung cancer (NSCLC) requiring integrating imaging, laboratory results, and molecular profiling to guide therapy.

Leyla O. Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease.

Explore effective management strategies for chronic graft-versus-host disease, focusing on transitioning from steroids to second-line therapies like ruxolitinib.

A patient with chronic graft-versus-host disease faces treatment challenges, highlighting the need for effective management strategies post-transplant.

A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance of multidisciplinary evaluation.

New findings reveal promising advancements in treating relapsed mantle cell lymphoma with BCL-2 inhibitors and novel agents, enhancing patient outcomes.

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved testing strategies and healthcare access.

Ramez N. Eskander, MD, discusses the optimal use of lenvatinib/pembrolizumab in clinical practice for patients with endometrial cancer. He provides advice for integrating this regimen into the treatment paradigm.